Biome Australia (BIO) H1 2026 earnings summary

Executive summary

• Achieved record H1 FY26 results with 40% revenue growth to AUD 12.4 million and net profit after tax of AUD 1.18 million, up 172% year-over-year, driven by strong sales in Activated Probiotics and new Activated Therapeutics lines.

• Eight consecutive quarters of positive EBITDA, with adjusted EBITDA reaching AUD 1.47 million and all product lines in growth.

• Maintained gross margin above 61% and EPS rose 165% to AUD 0.53.

• Distribution expanded to over 7,000 points in Australia, targeting 7,500 by year-end, with international expansion progressing in Canada, Ireland, UK, and New Zealand.

• Interim financial results and Vision 27 strategic plan update to be released on 23 February 2026, with an investor webinar scheduled for 25 February.

Financial highlights

• Revenue for H1 FY26 was AUD 12.4 million, up 40% year-over-year, with gross profit of AUD 7.58 million and gross margin at 61.1%.

• Net profit after tax was AUD 1.18 million, up from AUD 0.43 million in the prior year; EPS increased to 0.53 cents.

• Adjusted EBITDA of AUD 1.47 million, up 100% year-over-year.

• Operating cash flow of AUD 2.09 million, a turnaround from a prior year outflow, and borrowings reduced by AUD 1.4 million.

• Marketing spend remains lean at 7.5% of sales revenue.

Outlook and guidance

• On track to meet Vision 27 three-year plan, targeting AUD 80 million in cumulative sales.

• Winter Immunity Campaign and first major national advertising campaign to drive H2 growth.

• International sales targeted to exceed 10% of total, with long-term goal of equal market size in Australia, Europe, and North America.

• Ongoing clinical trial for proprietary BMB18™ strain expected to support future product development.

• Continued investment in sales and marketing to support domestic and international growth.